Neurogene, Inc. (NGNE)
28.31
-2.94
(-9.41%)
USD |
NASDAQ |
Sep 25, 16:00
28.32
+0.01
(+0.04%)
After-Hours: 19:59
Neurogene Debt to Equity Ratio : 0.0384 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0384 |
| March 31, 2026 | 0.0384 |
| December 31, 2025 | 0.0373 |
| September 30, 2025 | 0.0384 |
| June 30, 2025 | 0.0401 |
| March 31, 2025 | 0.0401 |
| December 31, 2024 | 0.04 |
| September 30, 2024 | 0.0955 |
| June 30, 2024 | 0.0889 |
| March 31, 2024 | 0.0844 |
| December 31, 2023 | 0.0805 |
| September 30, 2023 | 0.1421 |
| June 30, 2023 | 0.1388 |
| March 31, 2023 | 0.1436 |
| December 31, 2022 | -1.709 |
| September 30, 2022 | 0.1143 |
| June 30, 2022 | 0.1065 |
| March 31, 2022 | 0.0977 |
| December 31, 2021 | 0.0909 |
| September 30, 2021 | 0.0858 |
| June 30, 2021 | 0.0811 |
| March 31, 2021 | 0.0773 |
| December 31, 2020 | 0.0634 |
| September 30, 2020 | 0.059 |
| June 30, 2020 | 0.0824 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0797 |
| December 31, 2019 | 0.0085 |
| September 30, 2019 | 0.0092 |
| June 30, 2019 | 0.0063 |
| March 31, 2019 | 0.0001 |
| December 31, 2018 | 0.0001 |
| September 30, 2018 | 0.0001 |
| June 30, 2018 | 0.0003 |
| March 31, 2018 | 0.0003 |
| December 31, 2017 | 0.0003 |
| September 30, 2017 | 0.0003 |
| June 30, 2017 | 0.0003 |
| March 31, 2017 | 0.0003 |
| December 31, 2016 | 0.0003 |
| September 30, 2016 | 0.0002 |
| June 30, 2016 | 0.0006 |
| March 31, 2016 | 0.0008 |
| December 31, 2015 | 0.0012 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.002 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 244.36M |
| Total Liabilities (Quarterly) | 27.23M |
| Shareholders Equity (Quarterly) | 217.13M |
| Current Ratio | 10.63 |
| Net Debt Paydown Yield | 0.14% |